Biopharmaceutical firms are expanding messenger RNA applications beyond infectious disease vaccines into targeted therapies for rare genetic metabolic conditions.
Advanced Lipid Delivery
Improved lipid nanoparticle formulations allow precise tissue targeting, primarily directing therapeutic proteins to the liver and central nervous system without systemic toxicity.
Development Timelines
Modular RNA platforms enable rapid drug candidate iteration, substantially compressing early-stage discovery and preclinical testing phases.